This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The company’s myvac platform creates individualized immunotherapies that stimulate and “educate” a patient’s immune system to destroy cancer tumors. We use AI to select the targets most likely to induce a strong immune response and incorporate these neoantigens into our viral vector.”
The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.
You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.
The main questions that arise in such situations include: Is the adverse event related to a drug? Is the reaction due to an immune response to the drug (i.e. Collectively, drug allergy, intolerance and nonimmune drug hypersensitivity reactions have been estimated to comprise 25% of all adverse drug events.
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. ACIP plays a foundational role in shaping immunization policy in the US. Kennedy Jr.
The legislation also supports the use of mobile manufacturing units, offering close-to-home treatment for patients too unwell to travel, or whose weakened immune systems mean hospital visits carry extra risk.
This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP), a severe illness caused by drug-resistant bacteria, which disproportionately affects vulnerable populations, including children and the elderly as well as immune-compromised hosts like patients with diabetes, cancers etc.
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Development Library Events Press Releases PharmaVoice 100 Nominate 2024 PV100 2023 PV100 Sign up Search Sign up Search An article from Is biopharma dealmaking getting hot again?
Animals can be inaccurate testing models for human treatments, especially for disease states involving a human immune response, such as in cancer. 4 Testing also causes stress on the animals, leading to increased immune or biological responses and confounding disease data outcomes.
The lack of access to immunization services may lead to lower vaccination rates and vulnerabilities to infectious diseases in these communities. These deserts reduce access to critical health care services, such as vaccinations, health screenings, and point-of-care testing.
Treatment-related adverse events (AEs) included nausea (77.8% Baseline disease characteristics included stage IV disease in 89% (TN) and 95% (R/R) of patients, high-risk Mantle Cell Lymphoma International Prognostic Index scores in 11% and 15%, bulky disease over 5 cm in 17% and 30%, and blastoid morphology in 6% and 15%, respectively.
Reduced immunity from COVID-19 precautions and low vaccination rates, especially among children and vulnerable groups, worsened the influenza season's impact. Systemic inequities, misinformation, and geographic disparities hindered vaccination efforts, with significant coverage gaps among racial and rural populations.
Although some of these medications have additional FDA-approved uses (ie, rivaroxaban to reduce the risk of thrombotic vascular events in patients with peripheral artery disease), all 4 DOACs are approved for the treatment and prevention of venous thromboembolism and stroke prevention in nonvalvular atrial fibrillation (AFib).
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Addressing pharmacy deserts and enhancing interdisciplinary collaboration, especially with social workers, are crucial for improving health care access.
4 Novak added that these services align well with appointment-based models and can be layered with immunizations, chronic disease monitoring, and medication therapy management. Addressing Barriers and Finding Solutions Despite the promise of these services, challenges remain.
Despite its proven efficacy, the conventional oral administration of lenalidomide presents challenges due to its short half-life and the high systemic exposure required to sustain therapeutic drug levels, which can lead to significant toxicities, particularly grade 3 or 4 hematologic adverse events (AEs).
These events foster innovation, collaboration, and professional growth within the oncology pharmacy community. Participants can present their work, exchange ideas, and connect with leaders in the field during these networking opportunities.
Nacher : I think, as I said, rusfertide being a first-in-class hepcidin mimetic is huge—especially for patients with [PV]—to hopefully reduce the phlebotomy burden and prevent some of the sequelae of the disease, including cardiovascular and thrombotic events.
During the session “Collaborative Practice, Statewide Protocols, and Independent Prescriptive Authority: How Pharmacy is Expanding Services to Increase Access to Patients,” Klepser highlighted the importance of moving beyond product dispensing to provide higher-level services, such as immunizations and medication therapy management.
Community take-backs: Community groups may sponsor medication takeback events as well; however, they are typically short-term and must have a law enforcement officer in attendance. The patient can obtain a prepaid mailback envelope, fill it according to the directions, seal it, and mail it to the indicated location.
By meticulously reviewing medication regimens, reconciling discrepancies, and providing comprehensive education to patients and caregivers, they significantly reduce the likelihood of medication errors and adverse drug events during these vulnerable periods.
The regimen maintained stem cell collection feasibility with no new safety concerns, despite some adverse events like neutropenia and infections. MRD-negativity was observed in 63% of patients at a sensitivity threshold of 10⁻⁵, indicating deep therapeutic responses.
As a multifactorial condition influenced by both genetic predisposition and lifestyle factors, hypertension is a leading risk factor for serious health outcomes including microvascular complications (retinopathy and nephropathy) and macrovascular events (myocardial infarction and stroke).
Adverse events were common but comparable between dupilumab and placebo, with no deaths in the dupilumab group. The pivotal study showed dupilumab significantly improved disease remission and reduced corticosteroid use compared to placebo.
1 Population cohorts included adults ages 65 or older enrolled in Medicare and adults ages 19 to 64 years enrolled in Medicaid and deemed eligible for pneumococcal vaccination based on Advisory Committee on Immunization Practices recommendations. 1 Medicare enrollees were examined first.
July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook PsO is an immune-mediated disease characterised by rapid skin cell proliferation leading to inflamed plaques that can cause discomfort or pain. Credit: design_cam/Shutterstock.com.
Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone. Barriers to finerenone integration include cost, access, and existing MRA underutilization, with pharmacists crucial in educating prescribers and patients.
REMS ensured drug safety by requiring certified hospitals to have tocilizumab for severe adverse events management. Increased experience in managing CAR T therapy toxicities has led to the removal of REMS, facilitating broader access.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content